STOCK TITAN
  1. Home
  2. Sec-filings
  3. BSX
  4. [Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Boston Scientific (BSX) CFO adds 9,908 shares through discretionary 401(k) rebalancing

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Boston Scientific EVP and CFO Jonathan Monson reported an indirect acquisition of 9,908 shares of Boston Scientific common stock on 2026-08-10 at $50.46 per share. The footnote states this was a discretionary rebalancing election under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f). After this transaction, he indirectly holds 9,908 shares through the 401(k) and separately reports 39,063 shares held directly.

Positive

  • None.

Negative

  • None.
Insider Monson Jonathan
Role EVP and CFO
Type Security Shares Price Value
Discretionary Common Stock F1 9,908 $50.46 $500K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 9,908 shares (Indirect, By 401(k)); Common Stock — 39,063 shares (Direct)
Footnotes (1)
  1. F1. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
Indirect shares acquired 9,908 shares Discretionary 401(k) rebalancing transaction on 2026-08-10
Transaction price $50.46 per share Price for 9,908 indirectly acquired common shares
Indirect holdings after transaction 9,908 shares Indirect ownership via company 401(k) plan
Direct holdings reported 39,063 shares Directly owned Boston Scientific common stock after reported activity
Rule 16b-3(f) regulatory
"resulted in a discretionary transaction in shares of the Company's common stock."
401(k) Retirement Savings Plan financial
"under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction"
discretionary transaction financial
"which resulted in a discretionary transaction in shares of the Company's common stock."
indirect ownership financial
"indirectly holds 9,908 shares through the 401(k)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Boston Scientific (BSX) EVP and CFO Jonathan Monson report in this Form 4?
Jonathan Monson reported an indirect acquisition of 9,908 BSX shares of common stock at $50.46 per share, resulting from a discretionary rebalancing election under the company’s 401(k) Retirement Savings Plan on 2026-08-10.

How many Boston Scientific (BSX) shares does Jonathan Monson hold after this transaction?
Following the reported activity, Jonathan Monson holds 9,908 BSX shares indirectly via the company’s 401(k) plan and separately reports 39,063 BSX shares directly, according to the post-transaction ownership figures in the filing.

Was the Boston Scientific (BSX) Form 4 transaction by Jonathan Monson a market purchase?
The Form 4 describes the event as a discretionary transaction under Rule 16b-3(f) tied to a 401(k) plan rebalancing election, rather than a standard open-market purchase, even though it reflects an acquisition of 9,908 common shares.

At what price were Jonathan Monson’s new Boston Scientific (BSX) shares acquired?
The 9,908 indirectly held BSX shares associated with the 401(k) rebalancing transaction were reported at a price of $50.46 per share, as shown in the non-derivative transaction details for 2026-08-10.

How is the 401(k) ownership of Boston Scientific (BSX) shares characterized for Jonathan Monson?
The 9,908 BSX shares are reported as indirectly owned “By 401(k)”, reflecting holdings in the company’s 401(k) Retirement Savings Plan rather than direct personal brokerage ownership, with the transaction noted as discretionary under Rule 16b-3(f).
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Monson Jonathan
(Last)(First)(Middle)
300 BOSTON SCIENTIFIC WAY
(Street)
MARLBOROUGH MASSACHUSETTS 01752-1234
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP and CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026I(1)9,908A$50.469,908IBy 401(k)
Common Stock39,063D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
/s/ Susan Thompson, Attorney-in-Fact08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR